There are several mechanisms for the activation of the KEAP1-NRF2 pathway in cancer, including somatic mutations in KEAP1 or NRF2 that disrupt their binding, or accumulation of interfering proteins [20]. The gene discussed is KEAP1; the disease is cancer.